Thank you, Mr. Chair and committee members.
On behalf of the Juvenile Diabetes Research Foundation, thank you again for the opportunity to speak with you. You have our written proposal, and this afternoon I will touch on some highlights to bring together the illustration of the vision that this proposal looks to.
By means of introduction, JDRF has long been known as the leading funder of type 1 diabetes research on a not-for-profit, non-government basis. Just to put that into context, the leading government funder of type 1 research in the world continues to be the United States, which over a five-year plan is contributing $150 million a year in a dedicated fund to the National Institutes of Health for type 1 research.
JDRF is currently projecting, this year, $137 million to research, and next year the budget calls for $160 million. So very possibly next year we may change that sentence and leave out the non-government part.
JDRF has contributed a total of over $1 billion already. JDRF, several years ago, changed their research funding style, and we are proposing in this project something unique to the Canadian government. It is not a fund-and-forget request; it is a proposal for a unique and strategic partnership with the Canadian government to create a clinical trial network.
The proposal breaks down into two parts. The project to create a clinical trial network is on a 10-year initial term, and the specific request is, for the first five years, funding of $125 million. As I said, this is not on a fund-and-forget basis about which we'll get back to you in five years, at which point the researchers will tell you what happened.
JDRF's research management policies are founded on a business model. This implies and brings with it expertise that is not available elsewhere in the world. The business model calls for regular evaluations. There is a detailed proposal ready, which will show a tangible and measurable return on investment for this investment. That's the key word: we are looking for an investment in a partnership, not a handout that has no means of evaluation every six and 12 months.
We have had meetings with the Canadian Institutes of Health Research. In March, the CIHR announced the creation of a totally new element called their clinical research initiative. This is following up on Dr. Bernstein's open letter to researchers of January 6 of this year, which spoke of the need for CIHR, and in general for funding of health research in Canada, to move into what is called the transitional research stage.
How do you take basic discoveries and move them through this transitional gap to where venture capitalists and pharma companies find it in their commercial interests to take them the rest of the way towards commercialization?
This addresses existing Canadian strengths. Since 1921, and continuing right up to August 2007, Canada has had a particularly noted worldwide reputation as our researchers have led the world in significant achievements in type 1 diabetes. It also leverages existing Canadian research institutions, our leading hospitals and universities, because that is where the research is being done.
Such an initiative on a longer capital investment basis will allow them to leverage their own resources. Giving the universities and the hospitals a 10-year runway allows them to ramp up their own facilities and their own institutions as another form of leverage of this $125 million.
It also provides regular reporting on the progress of the investment by the only research institution in the world that's capable of doing this. This has already been recognized.
We have an agreement in principle with the Canadian Institutes of Health Research. We've held meetings, received the approval of Dr. Bernstein and his successor, the interim CEO, Dr. Chartrand, and the head of the Institute for Diabetes who would be most directly involved, Dr. Bhagirath Singh.
With tangible, measurable ROI being provided by JDRF, the reliability of what we are proposing can be independently verified because JDRF has concluded a similar type of effort in the United States, which resulted in a clinical trial network called the Immune Tolerance Network. The drawback of that particular facility is that it is almost always used to capacity.
JDRF concluded a similar project with the Australian government 18 months ago, which is just getting up and running. With all due respect, even the Australians admit they do not have the background and expertise to grow this very quickly, which narrows us down to existing Canadian research availability, capacity, world-leading achievements, and expertise.
The final element I'd like to highlight is that this network will forever leave a legacy in Canada because it will not be used 24/7 by type 1 research; it will then be available to research institutions for other disease research on an ongoing basis.
Merci.